Fuzuloparib

A PARP inhibitor used in cancer treatment

Fuzuloparib
[[File: Chemical structure of Fuzuloparib |220px|alt=Fuzuloparib]]

Fuzuloparib is a poly (ADP-ribose) polymerase (PARP) inhibitor that is used in the treatment of certain types of cancer. It is part of a class of drugs that target the DNA damage response pathway, which is crucial for the repair of single-strand breaks in DNA.

Mechanism of Action

Fuzuloparib works by inhibiting the activity of the PARP enzyme. PARP enzymes are involved in the repair of single-strand DNA breaks through the base excision repair pathway. Inhibition of PARP leads to the accumulation of DNA damage, ultimately resulting in cell death, particularly in cancer cells that are already deficient in other DNA repair mechanisms, such as those with BRCA1 or BRCA2 mutations.

Clinical Use

Fuzuloparib is primarily used in the treatment of ovarian cancer, breast cancer, and other cancers that have shown sensitivity to PARP inhibition. It is particularly effective in patients with BRCA mutations, as these mutations impair the homologous recombination repair pathway, making cancer cells more reliant on PARP-mediated repair.

Administration and Dosage

Fuzuloparib is administered orally. The dosage and treatment regimen depend on the specific type of cancer being treated, the stage of the disease, and the patient's overall health and response to the drug.

Side Effects

Common side effects of Fuzuloparib include nausea, fatigue, anemia, and thrombocytopenia. Patients may also experience more severe side effects such as myelodysplastic syndrome or acute myeloid leukemia, although these are less common.

Research and Development

Fuzuloparib is the subject of ongoing research to determine its efficacy in combination with other cancer therapies, such as chemotherapy and immunotherapy. Clinical trials are also exploring its use in other types of cancer beyond those with known BRCA mutations.

Related Pages

• PARP inhibitor
• BRCA1
• BRCA2
• Ovarian cancer
• Breast cancer